Kyntra Bio (KYNB) Accounts Payables (2014 - 2026)
Kyntra Bio (KYNB) posted Accounts Payables of $5.1 million for Q1 2026, up 36.02% sequentially from $3.7 million in Q4 2025, and down 30.05% YoY from $7.3 million in Q1 2025.
Kyntra Bio (KYNB) Accounts Payables (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Accounts Payables for 13 years, with the latest figure at $5.1 million in Q1 2026.
- Quarterly Accounts Payables fell 30.05% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (down 30.05% YoY) and the FY2025 annual result came in at $3.7 million, down 26.05% from the prior year.
- Accounts Payables rose to $5.1 million in Q1 2026 per KYNB's latest filing, from $3.7 million in the prior quarter.
- Over five years, Accounts Payables peaked at $71.3 million in Q1 2023 and troughed at $3.7 million in Q4 2025.
- A 5-year average of $17.4 million and a median of $10.5 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 96.08% in 2023, then slumped 93.89% in 2024.
- Over 5 years, Accounts Payables stood at $30.8 million in 2022, then tumbled by 48.7% to $15.8 million in 2023, then tumbled by 67.9% to $5.1 million in 2024, then slipped by 26.05% to $3.7 million in 2025, then jumped by 36.02% to $5.1 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $5.1 million, $3.7 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | 7.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.51 Mn |
| Mar 31, 2026 | 5.09 Mn |
| Dec 31, 2025 | 3.75 Mn |
| Sep 30, 2025 | 5.09 Mn |
| Jun 30, 2025 | 10.48 Mn |
| Mar 31, 2025 | 7.28 Mn |
| Dec 31, 2024 | 5.06 Mn |
| Sep 30, 2024 | 9.24 Mn |
| Jun 30, 2024 | 9.94 Mn |
| Mar 31, 2024 | 4.35 Mn |
| Dec 31, 2023 | 15.78 Mn |
| Sep 30, 2023 | 19.22 Mn |
| Jun 30, 2023 | 12.80 Mn |
| Mar 31, 2023 | 71.28 Mn |
| Dec 31, 2022 | 30.76 Mn |
| Sep 30, 2022 | 19.32 Mn |
| Jun 30, 2022 | 29.36 Mn |
| Mar 31, 2022 | 36.35 Mn |
| Dec 31, 2021 | 26.10 Mn |
| Sep 30, 2021 | 23.87 Mn |